
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Fails to Pass FDA Test for its Hepatitis C Drug
Boston, MA 10/01/2013 (wallstreetpr) – Share prices of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) fell by more than 58% yesterday after the drug regulators of the United States













